TCRX Stock — TScan Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT).

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.19

Market cap

$11.9M

Cash

$100.2M

Enterprise value

-$67.2M

Balance sheet

Cash	$100.2M
Debt	$21.1M
Net cash	$79.1M
Enterprise value	-$67.2M
Basic shares	67.8M shares
Fully diluted shares	152.1M shares
Fully diluted market cap	$28.9M
Cash per share	$1.48
Quarterly burn	$27.5M
Cash runway	3.6 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

67.8M

Pre-funded warrants

62.2M

Options

20.3M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

1.8M

FDSO

152.1M

Cap table as of 2026-06-30.

Price history

Loading TCRX daily closes…

Loading price history…

Next catalyst

TSC-204-A0201 · Feb 10 - Mar 24 in 14 wks · Phase 1 · Head and Neck Cancer; Cervical Cancer; Non-small Cell Carcinoma

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 10 - Mar 24 in 14 wks	TSC-204-A0201	Phase 1	Head and Neck Cancer; Cervical Cancer; Non-small Cell Carcinoma	—
Jul 13 - Aug 24 in 33 mo	TSC-101	Phase 3	AML; MDS	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

TSC-101

Phase 3 · Active Modality: TCR-engineered T cell (TCR-T) therapy

Target HA-2 (in patients with HLA type A*02:01)

Indications

Acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (HCT) (Phase 3)
Myelodysplastic syndromes (MDS) undergoing allogeneic HCT (Phase 3)

Status note Phase 3 registrational trial ALLOHA-2 in AML/MDS undergoing allogeneic HCT; first patient dosed Jul 2026. Phase 1 ALLOHA trial ongoing.

TSC-102-A01

Stage not disclosed · Active Modality: TCR-engineered T cell (TCR-T) therapy (allogeneic, donor-derived)

Target CD45 (HLA-A*01:01)

Indications

Hematologic malignancies undergoing HCT (Stage not disclosed)

Status note Donor-derived TCR-T candidate targeting CD45 in patients with HLA type A*01:01 undergoing HCT.

TSC-102-A03

Stage not disclosed · Active Modality: TCR-engineered T cell (TCR-T) therapy (allogeneic, donor-derived)

Target CD45 (HLA-A*03:01)

Indications

Hematologic malignancies undergoing HCT (Stage not disclosed)

Status note Donor-derived TCR-T candidate targeting CD45 in patients with HLA type A*03:01 undergoing HCT.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	TSC-101
Lead indication	AML
Lead phase	Phase 3
Active trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07702578	Phase 3	Recruiting	Sponsor	TCRX	—	AML; MDS	—
NCT05973487	Phase 1	Active, not recruiting	Sponsor	TCRX	—	Head and Neck Cancer; Cervical Cancer; Non-small Cell Carcinoma	—
NCT05473910	Phase 1	Recruiting	Sponsor	TCRX	—	AML; MDS	—
NCT06976736	Not disclosed	Recruiting	Sponsor	TCRX	—	AML; ALL; MDS	—
NCT05812027	Not disclosed	Active, not recruiting	Sponsor	TCRX	—	Head and Neck Cancer; Cervical Cancer; Non Small Cell Lung Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for TScan Therapeutics, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
BVF Partners	5,564,290	no change	0.14%	2026-08-14
Baker Bros. Advisors	2,784,792	no change	0.01%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

TCRX — TScan Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

TCRX — TScan Therapeutics Inc.